Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LTIZ warning on Amphocil

LTIZ warning on Amphocil

Liposome Technology Inc. has sent a letter to doctors in the U.K. advising them of adverse reactions in 21 patients

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE